- Title
- 15: To evaluate the efficacy and safety of VT-1161, a potent, highly selective inhibitor of fungal CYP51, in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC)
- Creators
- S. Brand - Viamet Pharmaceuticals (United States)T. Degenhardt - Viamet Pharmaceuticals (United States)P. Nyirjesy - Drexel UniversityJ. Sobel - Wayne State UniversityC. Handelsman - Viamet Pharmaceuticals (United States)K. Person - Viamet Pharmaceuticals (United States)R. Schotzinger - Viamet Pharmaceuticals (United States)A. Tavakkol - Viamet Pharmaceuticals (United States)
- Publication Details
- American journal of obstetrics and gynecology, v 215(6), pp S821-S821
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Other Identifier
- 991019350682904721
Journal article
15: To evaluate the efficacy and safety of VT-1161, a potent, highly selective inhibitor of fungal CYP51, in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC)
American journal of obstetrics and gynecology, v 215(6), pp S821-S821
Dec 2016
Metrics
15 Record Views